Drugs / Precision Multiple Antigen T Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02638857 | Sep 2015 → Mar 2017 | hepatocellular carcinoma | Second Military Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Precision Multiple Antigen T Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02638857 ↗ |
| Modality | Cell therapy | “PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin)” NCT02638857 ↗ |
| Route | Intravenous | “IV (in the vein)” NCT02638857 ↗ |